Notice of Results

Hutchison China Meditech Limited
28 February 2008


For Immediate Release





                    Hutchison China MediTech Limited ('Chi-Med')

                                   (AIM: HCM)


                        Notice of 2007 Preliminary Results



London, Thursday, 28 February 2008: Chi-Med will be announcing its preliminary
results for the year ended 31 December 2007 on Wednesday, 19 March 2008.



                                      Ends



Enquiries


Chi-Med                                      Telephone: [phone]
Christian Hogg, CEO

Citigate Dewe Rogerson                       Telephone: [phone]
Anthony Carlisle                             [phone]
David Dible                                  [phone]


About Chi-Med


Chi-Med is the holding company of a pharmaceutical and healthcare group focused
on traditional Chinese medicine ('TCM') based primarily in China and was
admitted to trading on the Alternative Investment Market of the London Stock
Exchange in May 2006. Chi-Med operates three core business segments: 1) China
healthcare - the manufacture, distribution and marketing of pharmaceuticals and
health supplements in China; 2) Drug R&D - the discovery and global development
of novel drug in the oncology and auto-immune therapeutic areas; and 3) Consumer
products - global retailing and distribution consumer health and personal care
products derived from TCM and botanical ingredients.



Chi-Med is majority owned by Hutchison Whampoa Limited, an international
corporation listed on the Main Board of The Stock Exchange of Hong Kong Limited.


                      This information is provided by RNS
            The company news service from the London Stock Exchange